{"id":"W2125877270","doi":"10.1158/1078-0432.ccr-11-3007","title":"A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma","year":2012,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Onyx Pharmaceuticals","keywords":"Carfilzomib; Medicine; Adverse effect; Tolerability; Dosing; Multiple myeloma; Pharmacokinetics; Proteasome inhibitor; Pharmacology; Refractory (planetary science); Internal medicine; Oncology; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003129835,0.0002772307,0.0009099926,0.00033343,0.0001698222,0.00002017007,0.000375788,0.000204275,0.0002267071],"category_scores_gemma":[0.007001357,0.0001400667,0.000151406,0.001282701,0.0009596485,0.0001921755,0.0003826765,0.0008559823,0.00001171696],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007863671,"about_ca_system_score_gemma":0.001727036,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001774498,"about_ca_topic_score_gemma":0.001337148,"domain_scores_codex":[0.9927383,0.002243364,0.001214399,0.0005840836,0.002213382,0.00100649],"domain_scores_gemma":[0.9941313,0.002889862,0.000370368,0.0009502647,0.001045144,0.0006130363],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.08381479,0.04996652,0.8167045,0.0002239024,0.0003522584,0.00008056845,0.001834957,5.941423e-7,0.001475026,8.745345e-7,0.0002794969,0.04526649],"study_design_scores_gemma":[0.09018154,0.03036032,0.8706772,0.0009683006,0.00008362891,0.000002556637,0.001645981,0.00005017907,0.005267855,0.000001353511,0.0006077599,0.0001533239],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926025,0.00026888,0.000001732016,0.000182095,0.0002131227,0.006495313,0.0001143086,0.00001797855,0.0001040894],"genre_scores_gemma":[0.9982553,0.00004035207,0.0001254419,0.0000400958,0.0002311244,0.0006483167,0.00001525085,0.00005871248,0.0005854784],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05397269,"threshold_uncertainty_score":0.8381784,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2172473456305167,"score_gpt":0.4730811051271257,"score_spread":0.255833759496609,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}